Quality & complianceOfficial

DOJ charges 15 in Los Angeles health care fraud takedown tied to $1.8bn in claims

🇺🇸 US Department of Justice · Thu 22 Oct 2026

US prosecutors allege sham addiction treatment, unnecessary atherectomies that injured patients, hospice fraud and bogus pharmacy prescriptions, in a case that includes six medical professionals.

The US Department of Justice announced on 22 October 2026 charges against 15 defendants, six of them medical professionals, over health care fraud schemes that allegedly produced more than $1.8bn in fraudulent claims to government and private health care programmes.

The largest element is a scheme in which over $1.6bn was billed to private insurers for sham substance abuse treatment. The department describes it as the largest case of its type it has ever prosecuted. Prosecutors allege that Nathan Young and David Young controlled dozens of purported treatment companies and directed 'body brokers', including Honey and Cody Phipps, to recruit vulnerable people such as those who were unhoused or attending support groups. The indictment alleges the defendants sought out policies with the most generous reimbursement and often enrolled people in policies for which they were not eligible.

Other cases include $134m billed to Medicare for unnecessary atherectomy procedures that allegedly injured patients, and over $138m billed to Medicare in three hospice schemes in which patients were not terminally ill. The department said the atherectomy case was detected through data analytics. A further defendant was indicted after earlier being charged by complaint over a $270m scheme to defraud Medi-Cal, California's Medicaid programme, through pharmacy claims for bogus prescriptions.

Eight defendants were arrested on the day. Six were expected to appear at the US District Court in downtown Los Angeles and two at a federal court in Texas. The FBI, HHS Office of Inspector General, IRS Criminal Investigation and the DEA's Los Angeles division were among the agencies cited in the announcement. The charges are allegations; the source text provided does not describe any outcomes.

What it means for your team

  • The announcement does not change pharmacovigilance or quality requirements, but it signals continued US enforcement focus on billing integrity and prescription-claim fraud.
  • Detection of unnecessary invasive procedures through data analytics suggests utilisation patterns are under scrutiny, which is relevant to teams working with real-world data or provider-facing programmes.
  • Compliance functions with US exposure may wish to review controls around pharmacy claims and prescription validity, given the Medi-Cal case.

Official source: US Department of Justice ↗

Article written by VigiEye from the official source (US Department of Justice). AI-assisted; check the source before acting.

More Quality & compliance All →